Page last updated: 2024-12-07

cp094

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

1,2-diethyl-3-hydroxypyridin-4-one: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID86322
CHEMBL ID72457
SCHEMBL ID868431
MeSH IDM0187415

Synonyms (28)

Synonym
1,2-diethyl-3-hydroxyhydropyridin-4-one
115900-75-9
hk-2
cp94
1,2-diethyl-3-hydroxy-pyridin-4-one
1,2-diethyl-3-hydroxy-4(1h)-pyridinone
4(1h)-pyridinone, 1,2-diethyl-3-hydroxy-
1,2-diethyl-3-hydroxypyridin-4-one
cgp 46700
CHEMBL72457
AKOS006272880
ccris 9395
g3px21x7iu ,
diethyl hydroxypyridinone
unii-g3px21x7iu
cp094
SCHEMBL868431
1,2-diethyl-3-hydroxypyridin-4-one; cgp 46700
DTXSID00151223
cp-94
1,2-diethyl-3-hydroxy-1,4-dihydropyridin-4-one
cgp-46700
cp 94
1,2-diethyl-3-hydroxypyrid-4-one
1,2-diethyl-3-hydroxypyridin-4(1h)-one
A903607
Z1198155563
EN300-1720867

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The bidentate chelators CP20 and CP94 (150 microM) appeared to be as effective as the hexadentate chelator desferrioxamine (50 microM) in the protection of rat and human hepatocytes against the toxic effect of iron load achieved by culturing the cells for 1 day in the presence of 50 microM iron citrate."( Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.
Brissot, P; Chenoufi, N; Cillard, J; Hubert, N; Lescoat, G; Loréal, O; Morel, I; Pasdeloup, N, 1995
)
0.29
" This method of enhancement was safely applied to a clinical PDT protocol with no unexpected adverse effects reported."( Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Campbell, S; Curnow, A; Pye, A, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of CP94 (100 mg/kg) was about 53%."( The pharmacokinetics of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in rats.
Damani, LA; Epemolu, OR; Hider, RC; Singh, S,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" The iron chelating hydroxypyridinone, CP94, has been administered prophylactically to iron overloaded gerbils in a dosing regime which favors the formation of bidentate chelated iron, to examine the possibility of additional toxicity being caused to the liver and heart by the bidentate chelated iron complex."( Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94.
Carthew, P; Dorman, B; Edwards, RE; Francis, JE; Hider, RC; Smith, AG, 1994
)
0.29
" Their pharmacokinetics were determined in rats to establish dosing parameters for microdialysis studies of BBB permeation."( The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat.
Allen, DD; Fredenburg, AM; Sethi, RK; Yokel, RA, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID363034Iron-clearing efficiency in po dosed [59Fe]ferritin-loaded Wistar rat assessed as iron removal2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
AID15965Partition coefficient (logD7.4)1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26251Partition coefficient (logD7.4) for iron(III) complexes1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID363030Octanol-MOPS buffer distribution coefficient, DC at pH 7.42008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
AID28984Partition coefficient (logD7.4)1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID577271Inhibition of soybean lipoxygenase at 100 uM after 15 mins2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
AID26627Ligand pka1 value was investigated by potentiometric titration1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID363033Antimalarial activity against chloroquine-resistant Plasmodium falciparum TM267TR after 24 hrs by [3H]hypoxanthine2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
AID23940Affinity constant log beta-3 value for Fe(III) complex1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID363032Iron-clearing efficiency in po dosed [59Fe]ferritin-loaded Wistar rat assessed as iron mobilization2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
AID179654Compound was tested in vivo for Iron mobilization efficacy against hepatocytes in normal fasted rats (loaded with [59Fe]-Ferritin).1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26551Affinity constant log K1 value for Fe(III) complex1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID19829Partition coefficient (logP)1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID26260Partition coefficient (logD7.4)1998Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18
Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
AID26838Ligand pka2 value was investigated by potentiometric titration1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID577273Inhibition of soybean lipoxygenase after 15 mins2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
AID26754log K3 value of the compound1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID26615Acid dissociation constant was determined1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID363024Dissociation constant, pKa corresponding to protonation of the 4-hydroxy group by spectrophotometric titration2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
AID24869pFe3+ (negative logarithm of the concentration of the free Iron(III) in solution) of the compound.1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID26568Affinity constant log K2 value for Fe(III) complex1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID26572log K2 value of the compound1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26573Affinity constant log K3 value for Fe(III) complex1999Journal of medicinal chemistry, Nov-18, Volume: 42, Issue:23
Synthesis, physicochemical characterization, and biological evaluation of 2-(1'-hydroxyalkyl)-3-hydroxypyridin-4-ones: novel iron chelators with enhanced pFe(3+) values.
AID363026Dissociation constant, pKa corresponding to dissociation of the 3-hydroxyl group by spectrophotometric titration2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26823Acid dissociation constant was determined1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
AID363031Partition coefficient, log P of the compound2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Basic 3-hydroxypyridin-4-ones: potential antimalarial agents.
AID577272Inhibition of soybean lipoxygenase at 10 uM after 15 mins2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID26567log K1 value of the compound1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Copper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's33 (64.71)18.2507
2000's11 (21.57)29.6817
2010's7 (13.73)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (5.17%)5.53%
Reviews1 (1.72%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other54 (93.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]